Jennifer L. Rocnik

1.3k total citations
12 papers, 553 citations indexed

About

Jennifer L. Rocnik is a scholar working on Hematology, Oncology and Molecular Biology. According to data from OpenAlex, Jennifer L. Rocnik has authored 12 papers receiving a total of 553 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Hematology, 4 papers in Oncology and 3 papers in Molecular Biology. Recurrent topics in Jennifer L. Rocnik's work include Chronic Myeloid Leukemia Treatments (6 papers), Acute Myeloid Leukemia Research (4 papers) and Cytokine Signaling Pathways and Interactions (3 papers). Jennifer L. Rocnik is often cited by papers focused on Chronic Myeloid Leukemia Treatments (6 papers), Acute Myeloid Leukemia Research (4 papers) and Cytokine Signaling Pathways and Interactions (3 papers). Jennifer L. Rocnik collaborates with scholars based in United States, Japan and Singapore. Jennifer L. Rocnik's co-authors include D. Gary Gilliland, Benjamin H. Lee, Neill A. Giese, Rachel Okabe, David P. Schenkein, Jin‐Chen Yu, Gary Gilliland, Yasuo Mori, Takahiro Shima and Koji Nagafuji and has published in prestigious journals such as SHILAP Revista de lepidopterología, Blood and Molecular Cell.

In The Last Decade

Jennifer L. Rocnik

11 papers receiving 543 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jennifer L. Rocnik United States 9 357 273 142 100 75 12 553
Sujata Chakraborty United States 10 272 0.8× 286 1.0× 146 1.0× 94 0.9× 44 0.6× 17 541
Koshi Akahane Japan 14 181 0.5× 301 1.1× 94 0.7× 217 2.2× 138 1.8× 63 658
William J. Kell United Kingdom 7 556 1.6× 325 1.2× 180 1.3× 126 1.3× 151 2.0× 13 726
Ksenia Bagrintseva Germany 7 483 1.4× 247 0.9× 243 1.7× 90 0.9× 65 0.9× 7 586
Ellen Wollmer Germany 7 250 0.7× 181 0.7× 88 0.6× 115 1.1× 49 0.7× 12 455
Kees Bol Netherlands 7 225 0.6× 259 0.9× 89 0.6× 283 2.8× 39 0.5× 10 537
Laura N Eadie Australia 12 381 1.1× 119 0.4× 249 1.8× 177 1.8× 110 1.5× 37 541
Adam Stine United States 8 641 1.8× 328 1.2× 289 2.0× 84 0.8× 95 1.3× 9 758
Serena Lavorgna Italy 16 484 1.4× 504 1.8× 118 0.8× 122 1.2× 144 1.9× 30 771
M Loos Belgium 7 299 0.8× 173 0.6× 196 1.4× 61 0.6× 103 1.4× 11 559

Countries citing papers authored by Jennifer L. Rocnik

Since Specialization
Citations

This map shows the geographic impact of Jennifer L. Rocnik's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jennifer L. Rocnik with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jennifer L. Rocnik more than expected).

Fields of papers citing papers by Jennifer L. Rocnik

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jennifer L. Rocnik. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jennifer L. Rocnik. The network helps show where Jennifer L. Rocnik may publish in the future.

Co-authorship network of co-authors of Jennifer L. Rocnik

This figure shows the co-authorship network connecting the top 25 collaborators of Jennifer L. Rocnik. A scholar is included among the top collaborators of Jennifer L. Rocnik based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jennifer L. Rocnik. Jennifer L. Rocnik is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

12 of 12 papers shown
1.
Gardberg, A.S., Valérie Vivat, Lei Cui, et al.. (2021). 765 The first-in-class small molecule TREX1 inhibitor CPI-381 demonstrates type I IFN induction and sensitization of tumors to immune checkpoint blockade. SHILAP Revista de lepidopterología. A800–A800. 3 indexed citations
2.
Conery, Andrew R., Jennifer L. Rocnik, & Patrick Trojer. (2021). Small molecule targeting of chromatin writers in cancer. Nature Chemical Biology. 18(2). 124–133. 26 indexed citations
3.
Ciccone, David, Jennifer L. Rocnik, Ian D. Linney, et al.. (2020). Abstract 942: HPK1, hematopoietic progenitor kinase 1, is a promising therapeutic target for cancer immunotherapy. Cancer Research. 80(16_Supplement). 942–942.
4.
Wei, Ling, David Hollenback, Saritha Kusam, et al.. (2018). ACC inhibitor demonstrates potent anti-fibrotic activity in vitro and in vivo. Journal of Hepatology. 68. S399–S400. 2 indexed citations
5.
Akahane, Koshi, Zhaodong Li, Julia Etchin, et al.. (2017). Anti‐leukaemic activity of the TYK2 selective inhibitor NDI‐031301 in T‐cell acute lymphoblastic leukaemia. British Journal of Haematology. 177(2). 271–282. 28 indexed citations
6.
Akahane, Koshi, Zhaodong Li, Julia Etchin, et al.. (2016). Anti-Leukemic Activity of the TYK2 Selective Inhibitor Ndi-031301 in T-Cell Acute Lymphoblastic Leukemia. Blood. 128(22). 1596–1596. 8 indexed citations
7.
Munson, Mark, et al.. (2015). Lead optimization attrition analysis (LOAA): a novel and general methodology for medicinal chemistry. Drug Discovery Today. 20(8). 978–987. 11 indexed citations
8.
Mounir, Zineb, Fallon Lin, Joshua M. Korn, et al.. (2014). TMPRSS2:ERG blocks neuroendocrine and luminal cell differentiation to maintain prostate cancer proliferation. Oncogene. 34(29). 3815–3825. 46 indexed citations
9.
Yoshimoto, Goichi, Toshihiro Miyamoto, Siamak Jabbarzadeh‐Tabrizi, et al.. (2009). FLT3-ITD up-regulates MCL-1 to promote survival of stem cells in acute myeloid leukemia via FLT3-ITD–specific STAT5 activation. Blood. 114(24). 5034–5043. 200 indexed citations
10.
Keersmaecker, Kim De, Jennifer L. Rocnik, Rafael Bernad, et al.. (2008). Kinase Activation and Transformation by NUP214-ABL1 Is Dependent on the Context of the Nuclear Pore. Molecular Cell. 31(1). 134–142. 47 indexed citations
11.
Meshinchi, Soheil, Derek L. Stirewalt, Todd A. Alonzo, et al.. (2008). Structural and numerical variation of FLT3/ITD in pediatric AML. Blood. 111(10). 4930–4933. 77 indexed citations
12.
Rocnik, Jennifer L., Rachel Okabe, Jin‐Chen Yu, et al.. (2006). Roles of tyrosine 589 and 591 in STAT5 activation and transformation mediated by FLT3-ITD. Blood. 108(4). 1339–1345. 105 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Sujata Chakraborty Breakdown of academic impact, for papers by Koshi Akahane Breakdown of academic impact, for papers by William J. Kell Breakdown of academic impact, for papers by Ksenia Bagrintseva Breakdown of academic impact, for papers by Ellen Wollmer Breakdown of academic impact, for papers by Kees Bol Breakdown of academic impact, for papers by Laura N Eadie Breakdown of academic impact, for papers by Adam Stine Breakdown of academic impact, for papers by Serena Lavorgna Breakdown of academic impact, for papers by M Loos
Rankless by CCL
2026